Menu
1 min read · estimated
APPROVED USE
What FDA approved
For advanced renal cell carcinoma after treatment with a PD-1 or PD-L1 inhibitor and a VEGF-directed tyrosine kinase inhibitor.
LAMPGEN ANALYSIS
Why it matters
This decision brought HIF-2α inhibition into a post-immunotherapy and post-VEGF setting.
What research teams should watch
Verify both prior therapy classes and plan hemoglobin and oxygen-saturation monitoring.
PRIMARY RECORDS